Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment.
Increased understanding of how variants in genes encoding metabolising enzymes, transporters and receptors affect drug efficacy and toxicity, in parallel with advances in genotyping technology means that clinical pharmacogenetics is drawing tantalisingly close to reality. This review considers some of the pharmacogenetic variants that have been described that are relevant to the management of women with breast cancer and how these may soon translate into clinical practice.
Blackhall
Fiona H
FH
Department of Medical Oncology, Christie Hospital NHS Trust, M20 2BX, Manchester, UK.
Howell
Sacha
S
Newman
Bill
B
D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D010597:Pharmacogenetics; D013629:Tamoxifen / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D013629:Tamoxifen